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Abstract 
Background: Although biochemical analysis of HIV-1 integrase enzyme suggested the use of integrase inhibitors 
(INIs) against HIV-1C, different viral subtypes may favor different mutational pathways potentially leading to varying 
levels of drug resistance. Thus, the aim of this study was to search for the occurrence and natural evolution of inte-
grase polymorphisms and/or resistance mutations in HIV-1C Ethiopian clinical isolates prior to the introduction of INIs.
Methods: Plasma samples from chronically infected drug naïve patients (N = 45), of whom the PR and RT sequence 
was determined previously, were used to generate population based sequences of HIV-1 integrase. HIV-1 subtype was 
determined using the REGA HIV-1 subtyping tool. Resistance mutations were interpreted according to the Stanford 
HIV drug resistance database (http://hivdb.stanford.edu) and the updated International Antiviral Society (IAS)-USA 
mutation lists. Moreover, rates of polymorphisms in the current isolates were compared with South African and global 
HIV-1C isolates.
Results: All subjects were infected with HIV-1C concordant to the protease (PR) and reverse transcriptase (RT) 
regions. Neither major resistance-associated IN mutations (T66I/A/K, E92Q/G, T97A, Y143HCR, S147G, Q148H/R/K, and 
N155H) nor silent mutations known to change the genetic barrier were observed. Moreover, the DDE-catalytic motif 
(D64G/D116G/E152 K) and signature HHCC zinc-binding motifs at codon 12, 16, 40 and 43 were found to be highly 
conserved. However, compared to other South African subtype C isolates, the rate of polymorphism was variable at 
various positions.
Conclusion: Although the sample size is small, the findings suggest that this drug class could be effective in Ethiopia 
and other southern African countries where HIV-1C is predominantly circulating. The data will contribute to define the 
importance of integrase polymorphism and to improve resistance interpretation algorithms in HIV-1C isolates.
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Background
HIV replication requires three viral enzymes and acces-
sory metabolites provided by the infected cell. The viral 
enzymes protease (PR), reverse transcriptase (RT), and 
Integrase (IN), encoded by the polymerase (pol) gene 
are the main targets of current antiretroviral drugs [1]. 
HIV-1 IN is a 288 amino acid (aa) protein encoded by 
the 5′ end of the pol gene that folds in a multimeric form 
into 3 functional domains: the N-terminal domain (NTD: 
aa 1–49) contains an HHCC zinc binding motif which 
is essential to facilitate IN multimerization through its 
extensive contacts with adjacent catalytic core domain 
(CCD) monomers; the CCD (aa 50–212) contains the 
DDE motif of the catalytic triad D64, D116 and E152 and 
the viral DNA binding site; and the C-terminal domain 
(CTD: aa 213–288) has host DNA binding activity [2–5]. 
IN is responsible for chromosomal integration of the 
newly synthesized double strand viral DNA into the host 
genomic DNA [2]. This chromosomal integration is a 
multistep process grouped in 3 major steps. The first is 
the formation of the pre-integration complex (which 
allows entry of viral genomes into the cell nucleus). The 
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proviral DNA for integration. During this process, IN 
recognizes conserved sequences in the long terminal 
repeats promoting the removal of GT dinucleotide from 
the 3ʹ end, resulting in new 3′ hydroxyl ends [2]. This step 
occurs in the cytoplasm and involves the pre-integration 
complex, which consists of both viral and cellular pro-
teins that help the pre-integration complex to migrate 
through nuclear pores [6]. The final step is strand transfer 
in which target DNA is cleaved and viral DNA is joined 
to the 5′ phosphate ends in the host chromosome which 
is most likely completed by the host DNA repair machin-
ery [2]. These enable HIV-1 to establish a permanent 
genetic reservoir that can initiate new virus’s production 
and to replicate through cellular mitosis [4, 5].
In industrialized countries integrase strand transfer 
inhibitors have been shown to lead to virological sup-
pression in both treatment naïve patient as well as treat-
ment-experienced individuals with multidrug-resistance 
to other drug classes [7]. However, drug resistance to 
this drug class has been shown to occur both in vivo and 
in vitro [8, 9]. Currently, there are more than 40 substi-
tutions specifically associated with the development of 
resistance to integrase inhibitors (INIs). Yet, the main 
mutational pathways associated with INIs resistance are 
limited to signature mutations at IN positions 66, 92, 143, 
147, 148, and 155 [8–10]. The prevalence of INIs resist-
ant viral strains has not yet been reported; although some 
studies have found that 95 % of HIV-1B-infected patients 
treated with this drug class were susceptible and showed 
viral suppression [7–9]. Even though biochemical analy-
sis of HIV-1B and C integrase enzymes suggested the use 
of INIs against HIV-1C, recent studies have indicated 
that different viral subtypes may favor different muta-
tional pathways potentially leading to varying levels of 
drug resistance among different subtypes and within the 
same subtype in different regions [11–13]. On top of that, 
IN sequence data on HIV-1C which is the most preva-
lent circulating clade in sub-Saharan African countries is 
lacking [12, 13]. So, it is worth enough to conduct spe-
cific studies on the HIV-1C subtype. Besides, an increas-
ing number of patients in sub-Saharan African countries 
require alternative regimes as they fail first and second 
line regimes containing non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), nucleoside reverse tran-
scriptase inhibitors (NRTIs) and protease inhibitors (PIs) 
due to transmitted or secondary drug resistance muta-
tions [14–20]. This is in line with our findings of a high 
rate of mutations conferring resistance to NNRTIs and 
NRTIs inhibitors in treatment naïve [19, 20] and treated 
Ethiopian patients [21]. Thus, the aim of this study was to 
search for the occurrence and natural evolution of inte-
grase polymorphisms and/or integrase inhibitors (INIs) 
resistance mutations in HIV-1C clinical isolates of ART 
naïve Ethiopian patients prior to the introduction of INIs 




HIV-1C chronically infected treatment naïve patients 
above 18  years of age and seeking treatment at Gondar 
University Hospital, Northwest Ethiopia in 2008 were 
recruited consecutively. The inclusion and exclusion cri-
teria and the baseline characteristics of the patients and 
sample collection were described before [20]. Briefly, five 
ml venous blood was collected in vacutainer tubes con-
taining ethylene diamine tetraacetic acid. Baseline CD4+ 
T cell count was measured using the FACSCount flow 
cytometer (Becton–Dickinson, San Jose, CA, USA) fol-
lowing the manufacturer’s protocol. Plasma samples were 
separated by centrifugation and stored at −40  °C. RNA 
extraction and plasma viral load determination was made 
with the Abbott m2000sp automated sample prepara-
tion system using mSample preparation system RNA kit 
and Abbott m2000rt using Quantitative Realtime HIV-1 
assay, respectively (Abbott Molecular, Des Plaines, IL, 
USA). The lower detection limit of the assay is 40 copies/
ml.
Amplification and sequencing
The IN region of the pol gene of the HIV-1 genome was 
amplified by using an in-house protocol. RNA elute was 
reverse transcribed to cDNA using AMV reverse tran-
scriptase (Promega Corporation, WI, USA) by an outer 
primer HIVINT-Rev1 (5′TGGGATGTGTACTTCTGA 
ACTTA3′ corresponding to positions 5192-5214) at 
50 °C for 1 h. Viral cDNA was amplified by nested PCR 
using Phusion Hot Start High-Fidelity DNA polymerase 
(Finnzymes, Espoo, Finland) by outer primers HIVINT-
For1 (5′AAAGGAATTGGAGGAAATGAAC3′ corre-
sponding to positions 4167-4188) and HIVINT-Rev1 
and inner primers HIVINT-For2 (5′GAAATGAACAA-
GTAGATAAATTAGTAAG3′ corresponding to positions 
4180-4204) and HIVINT-Rev2 (5′CCTGCCATCTG 
TTTTCCATA3′ corresponding to position 5040–5059). 
Initial denaturation was done at 98  °C for 2  min fol-
lowed by 40 cycles consisting of 10  s of denaturation at 
98  °C and 25  s of annealing at 64  °C for the first round 
and at 58 °C for the second round with a 40 s extension 
at 72 °C for both and final extension for 5 min at 72 °C. 
All positions are matched to HIV-1 HXB2 (GenBank 
accession number K03455). The RT-PCR products which 
showed a clear band on agarose gel were cut-off and puri-
fied by Wizard Promega PCR clean-up system (Promega, 
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Madison, WI, USA) according to the manufacturer’s 
instructions.
Purified PCR products (PCR Clean-up System, Pro-
mega) were subjected to direct sequencing of both the 
sense and antisense strands using Big Dye Terminator 
Cycle Sequencing Ready Reaction kit (Applied Biosys-
tems Incorporated, Foster City, CA, USA). Sequencing 
was performed using the two inner primers which 
allowed a double coverage of the IN genome. After 
running the sequencing reaction, non-incorporated 
dideoxynucleoside triphosphates were removed by eth-
anol-sodium acetate precipitation and dried by vacuum 
centrifugation for 12 min. The pellet was re-suspended in 
20 µl high density formamide (Applied Biosystems Incor-
porated, Foster City, CA, USA) for denaturation and 
loading on the ABI prism 310 Genetic Analyzer (Applied 
Biosystems). Both forward and reverse overlapping 
sequences were manually edited with the Geneious Basic 
software version 5.4 and exported as a FASTA format 
consensus sequences. Sequences were aligned with refer-
ence set from the Los Alamos HIV database (http://www.
hiv.lanl.gov) using the Mega version 5 software (http://
www.megasoftware.net) and phylogenetic inferences 
were performed by the Neighbour-Joining (NJ) method 
under Kimura’s two-parameter correction. One thousand 
bootstrap replicates were used to assess the phylogenetic 
robustness of the clusters. Moreover, the REGA HIV-1 
subtyping tool was used for each sequence to determine 
the HIV-1 subtype.
Drug resistance analysis
Drug resistance mutations were analysed using The 
Stanford University HIV drug resistance database 
(http://hivdb.stanford.edu) and the 2015 updated drug 
resistance mutations list of the International Antiviral 
Society (IAS-USA) [22]. Although, frequency cut-off to 
distinguish polymorphic from non-polymorphic posi-
tions has not been proposed amino acid changes with 
a prevalence of at least 3  % among treatment-naive 
patients were considered, as used previously [23]. The 
rates of polymorphisms in the current study were also 
compared with South African subtype C (N = 72) spe-
cific polymorphisms reported by Fish et al. [12] and with 
the Global HIV-1 subtype C (N = 1044) isolates (http://
hivdb.stanford.edu).
Statistical analyses
The data was analysed using to SPSS version 17 statisti-
cal packages. HIV-RNA loads were transformed to log10 
for analysis. Data were summarized as medians and 
interquartile range (IQR). Non-parametric tests were 
performed to compare median CD4+ T cells count and 
plasma HIV-RNA levels of the different groups.
Ethical approval
The study protocol and design including the consent 
procedures were approved by the University of Gondar 
Ethical Review Committee (RPO/55/291/00). Patients 
were managed following the national guideline. Written 
informed consent was obtained from all study subjects 
and documented in Research Office of the University.
Results
From the total of 45 patients enrolled in this study, 53 % 
were females. The mean  ±  SD age of the subjects was 
33  ±  1.6  years ranging from 24 to 58  years. There was 
no significant difference in the mean age among males 
and females (32.4 versus 34.5, respectively; P  =  0.086). 
According to the WHO AIDS stage defining criteria, 
15.6 % (7/45), 20 % (9/45), 55.6 % (25/45) and 8.8 % (4/45) 
of the patients were classified into stage one, two, three 
and four, respectively. Baseline median CD4+ T cell count 
was 103 cells/mm3 (IQR: 57.0–287.0) and the propor-
tion of patients with CD4+ T cell count ≤200 and >201 
cells/mm3 was 62 and 38 %, respectively. The mean log10 
HIV-1 RNA level of the patients was 4.54 and did not 
significantly differ among patients with higher and lower 
CD4+ T cells strata (log10 4.65 for >201 cells/mm3 versus 
log104.4 for ≤200 cells/mm3). As previously reported [20] 
in this group of well characterized patients, two patients 
had NNRTI associated mutations (G190A and E138G) 
and one patient had a NRTI resistance-associated muta-
tion (L210 W). A subtype C-specific polymorphism asso-
ciated with NRTIs (V118I) was detected in one patient. 
No major drug resistance mutations in PR region were 
found (Table 1). However, the presence of subtype C spe-
cific polymorphisms and minor resistance mutations to 
protease inhibitors were detected frequently.
The 45 nearly full-length nucleotide sequences of the 
IN region covering the first 269 amino acids (93  % of 
the IN gene) were with intact with open reading frames 
and without frameshift deletion or insertion confirm-
ing the presence of functional IN genes in all patients 
and primary virus isolates. However, a deletion of 6 and 
12 amino acids in the catalytic core domain-CCD from 
codon 122 to codon 127 and from codon 188 to codon 
199 was observed in two of the samples (5550 and 
5713) obtained from a 43 years old male and a 38 years 
old female patient with baseline log10 HIV RNA level 
of 4.66 and 3.86 and CD4+ T cell count of 209 and 182 
cells/mm3, respectively. Such a massive deletion has not 
been observed in several HIV-1C and other sequences 
available in HIV database. The IN intra-subtype nucleo-
tide diversity varied between 1.7% and 5.4  % which is 
similar to what has been reported previously from South 
African subtype C IN sequences [12, 13]. All sequences 
were found to be HIV-1C in concordance with the 
Page 4 of 8Mulu et al. J Transl Med  (2015) 13:377 
Table 1 HIV-1 genotype drug resistance profile to PRI, RTI and INIs of chronically infected HIV-1 subtype C patients
M Male, F Female, HIV RNA in log10 copies/ml; CD4
+ T cell count (cells/mm3); PRI protease inhibitors, RTI reverse transcriptase inhibitors, INI integrase inhibitors, S 
susceptible, R resistance
ID Age/sex RNA CD4 count Resistance to PRIs Resistance to RTIs Resistance to INIs
5572 28/M 5.18 20 Minor R (V11FV) S S
5492 30/F 5.38 27 S S S
5493 23/F 5.28 33 S S S
5790 45/M 4.18 37 S S S
5531 24/F 6.17 38 S S S
5655 29/F 3.75 48 S S S
5551 28/M 4.66 59 S S S
5642 25/F 4.01 60 S S S
5775 45/F 3.85 61 S S S
5595 25/M 4.32 66 S S S
5592 55/M 5.82 75 S S S
5717 28/F 4.21 75 S S S
5525 30/F 4.79 80 S S S
5648 35/F 5.04 85 S S S
5591 33/M 4.37 85 S S S
5582 32/M 5.43 89 S S S
5568 36/M 3.90 92 S S S
5499 35/M 5.91 97 S S S
5604 27/M 4.64 97 S S S
5517 25/F 3.83 112 S S S
5627 30/F 3.08 115 S S S
5732 36/F 5.14 118 S S S
5479 35/F 5.44 124 S R–NNRTIs (E138G) S
5546 38/F 4.33 125 S S S
5841 58/M 4.47 129 S S S
5733 32/F 4.78 146 S S S
5713 38/F 3.86 182 S S S
5681 28/M 4.38 191 S S S
5550 43/M 4.66 209 S S S
5786 27/F 3.88 211 S S S
5837 28/F 3.76 212 S S S
5768 44/M 5.91 219 S S S
5712 39/M 4.82 224 S R–NNRTIs (G190A) S
5669 40/F 3.57 227 Minor R (L10I) S S
5585 47/F 4.60 227 S S S
5596 27/F 4.8 238 S S S
5511 20/F 4.54 262 S S S
5524 42/M 3.90 269 S S S
5485 40/M 4.50 277 S S S
5690 30/M 3.30 312 S S S
5530 24/F 3.81 336 S S S
5582 34/M 5.43 366 S S S
5630 28/M 4.17 401 S S S
5511 24/F 4.54 421 S S S
5496 40/M 3.88 751 S R–NRTIs (L210 W) S
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corresponding PR and RT sequences [19] which is addi-
tional evidence for clade homogeneity in the region. Phy-
logenetic analysis of the integrase nucleotide sequences, 
together with viruses from the major subtypes, revealed 
that the majority of sequences clustered with Ethiopian 
HIV-1C isolates which indicates that the majority of the 
current Ethiopian HIV-1 epidemic descended from a sin-
gle introduction into the country (Fig. 1). Clear cluster of 
sequences with sequences of other countries (Brazil, S. 
African and Indian and China) was also observed indicat-
ing that HIV-1 subtype sequences from these countries 
are inter-related and/or subtype C in Ethiopia may have 
been introduced from these countries HIV-1C lineages. 
None of the isolates revealed recombination.
Table  2 shows the frequency of the IN sequences 
with mutations and/or polymorphisms associated with 
reduced susceptibility to INIs. As expected, none of the 
samples contained mutations associated with primary 
resistance to INIs and all the isolates were found to be 
susceptible for INIs (Tables 1, 2). Moreover, the DDE-cat-
alytic motif (D64G/D116G/E152 K) and signature HHCC 
zinc-binding motifs at codon 12, 16, 40 and 43 were 
found to be highly conserved. Silent mutations leading to 
higher increment of genetic barrier were not detected in 
the current study. However, polymorphic and non-poly-
morphic changes were observed (Table 2). Three patients 
(6.7  %) had minor INI-resistance mutations, i.e. L74  M 
and T97A. Unusual mutations at minor INI-resistance 
positions were observed in small number of patients 
(Table 2). Two polymorphic minor INI-accessory muta-
tions (V201I and I203 M) occurred in 82.2 and 13.3 % of 

































































































Fig. 1 Phylogenetic relationships of the IN HIV-1C sequences (4 digit number-GenBank Accession number: KF959731-KF959775) with different 
HIV-1 subtype reference sequences from the Los Alamos database (http://hiv-web.lanl.gov). Bootstrap values greater than 70 % are indicated
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the current study compared with South African HIV-1C 
specific polymorphisms [12] were similar at 6 positions, 
but significantly higher at 8/21 positions and significantly 
lower at 7/21 positions (Fig. 2).
Discussion
In this study, the IN aa sequence alignment was screened 
for the presence of major mutations, non-polymorphic 
and polymorphic changes associated with resistance to 
INIs (http://hivdb.stanford.edu) and additionally was cat-
egorized according to a previous report associated with 
INI resistance [23] (1) Major INI-resistance mutations 
were defined as mutations that phenotypically decrease 
susceptibility to raltegravir or elvitegravir by fivefold 
or higher and have been reported to be selected by one 
of these INIs in  vitro or in  vivo. This includes T66IAK, 
E92Q, F121Y, G140SA, Y143HCR, Q146P, S147G, 
Q148KHR, and N155HS; (2) minor INI-resistance muta-
tions were defined as non-polymorphic or minimally 
polymorphic mutations that reduce INI susceptibil-
ity <fivefold by themselves or that significantly contrib-
ute to resistance when they occur in combination with 
other mutations (H51Y, L74  M, T97A, E138AK, S153Y, 
E157Q, G163RK, S230R, and R263 K); and (3) minor INI 
accessory mutations were defined as highly polymorphic 
mutations that have been reported to occur more fre-
quently among INI-treated than INI naive patients but 
which have not been shown to contribute to reduced INI 
susceptibility (V68VI, V151IA, M154IL, V201I, I203  M, 
and S230 N).
The present study describes for the first time the occur-
rence of natural genetic polymorphisms in the IN region 
among HIV-1C isolates from the Horn of Africa and 
identifies the frequency of natural polymorphisms asso-
ciated with resistance to INIs in samples from chronically 
infected antiretroviral drug-naïve patients. The absence 
of mutations associated with primary resistance to INIs 
and silent mutations (e.g. at codon 151) leading to higher 
increment of genetic barrier [24] is as expected and simi-
lar with previous reports from South Africa [11, 12], 
Mozambique [25], Cameron [26], Brazil [27], Quebec 
[28] and other parts of the world [23]. The occurrences 
of polymorphic minor INI-accessory mutations (L74I, 
Table 2 Pattern and  frequency mutations and  polymor-
phisms with potential impact on INIs reduced susceptibil-
ity of INIs among HIV-1 subtype C (n = 45)
a Unusual mutations in non-polymorphic sites associated with minor INI 
mutations (according to The Stanford University HIV drug resistance database; 
http://hivdb.stanford.edu)
Minor INI-resistance mutations Frequencey





G163 Va 2 (4.4)
G163 Wa 3 (6.6)
Minor INI accessory mutations
 V201I 37 (82.2)
 I203 M 6 (13.3)
Fig. 2 Distribution of HIV-1C IN sequences polymorphic and non-polymorphic changes of the present study (ETH 2008/2009) compared with the 
South African HIV-1C (SA 2009) [12] and global HIV-1C sequences (http://hivdb.stanford.edu)
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T125A, V165I, T206S, L234I and V201I) are similar to 
previous HIV-1C isolates from South Africa [11, 12]. 
However, the variations on the rates of polymorphisms 
observed in the current study compared with South 
African subtype C specific polymorphisms [12] (Fig.  2) 
suggest the presence of intra-subtype region-specific 
differences.
The current study shows regional specific polymor-
phic and non-polymorphic changes as reported previ-
ously from southern Africa, Brazil and Quebec [28]. The 
absence of the non-polymorphic minor INI-resistance 
mutations (E157Q which could be selected by raltegravir 
reducing elvitegravir susceptibility) in the current study 
is similar with a recent report from Brazilian subtype 
C isolates [27] and several other studies [23, 29]. But, it 
was inconsistent with the findings from Quebec [28] and 
from South Africa [11, 12] reported in 35 and 4.1 % of the 
isolates, respectively suggesting subtype C regional vari-
ations involving epidemics from Ethiopia, South Africa 
and Quebec. On the other hand, a highly polymorphic 
minor INI accessory mutation (V201I) was detected in 
82  % of the isolates which is significantly higher com-
pared with the report from Cameron [26] and Quebec 
[28] subtype C isolates and consistent with South Afri-
can isolates [11, 12]. These findings may explain the 
differing rates of acquisition and accumulation of muta-
tions in subtype C isolates [30–32]. Although the sig-
nificance of these residues to the current generation of 
INIs is not yet well known, the current findings show 
the need for surveillance of IN mutations and HIV-1C 
region specific phenotypic studies to explain the rel-
evance of the naturally occurring polymorphisms in the 
absence of the signature IN mutations on susceptibility/
resistance to INIs.
Conclusion
None of the previously reported major mutations 
(T66AIK, E92Q, Y143RCH, S147G, Q148HRK and 
N155H) associated with resistance to INIs were observed 
in HIV-1C Ethiopian isolates, indicating that INIs can be 
used as a treatment option in Ethiopia and other Afri-
can countries where HIV-1C is predominately circulat-
ing. However, the IN sequence variations found in the 
present study compared with other African subtype C 
isolates needs further investigation. The findings of the 
present study may be useful not only to explain natural 
IN genetic polymorphism but also to improve resistance 
interpretation algorithms in HIV-1C isolates about which 
very little is known.
Sequence data: Nucleotide sequences are depos-
ited in National Centre for Biotechnology Informa-
tion (NCBI), USA with Accession number [GenBank: 
KF959731-KF959775].
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